Quantcast

Latest Proteasome Stories

2009-02-23 14:25:00

CAMBRIDGE, Mass., Feb. 23 /PRNewswire/ -- Millennium: The Takeda Oncology Company today announced that 100 data presentations on VELCADE research will be featured at the Fifth International Myeloma Workshop (IMW) in Washington, D.C., February 26 - March 1, 2009. The 13 oral and 87 poster presentations will include updated results on overall survival and safety of VELCADE based therapies in patients with relapsed or previously untreated multiple myeloma (MM). (Logo:...

2009-02-13 10:03:00

Researchers at Fox Chase Cancer Center have demonstrated that it might be possible to treat genetic diseases, including some forms of cancer, by "rescuing" the misshapen, useless proteins produced by some mutant genes.In the current issue of the Journal of Biological Chemistry, available online now, researchers detail how they were able to restore the function of a mutant human gene in a yeast model of disease by manipulating the available amounts of a so-called chaperone protein, named...

2009-02-03 14:30:00

WASHINGTON, Feb. 3 /PRNewswire-USNewswire/ -- Green tea products have become regarded as a valuable health supplement, as studies have shown evidence of its benefit against a variety of diseases, including cancer. However, a new study suggests that some components of green tea may counteract the anticancer effects of one cancer therapy, bortezomib (Velcade(R)), and may be contraindicated for patients taking this medicine to ensure its maximum therapeutic benefit. This study is being...

2009-01-16 16:25:15

Singapore scientists report findings in Molecular CellResearchers at A*STAR's Institute of Molecular and Cell Biology (IMCB) have become the first to discover and characterize a human protein called Bax-beta (BaxÃŽ²), which can potentially cause the death of cancer cells and lead to new approaches in cancer treatment. The finding is published in the 16 Jan. report of Molecular Cell.Detection of BaxÃŽ² has eluded scientists until now. Said Dr Victor Yu,...

2008-12-09 09:00:00

SOUTH SAN FRANCISCO, Calif., Dec. 9 /PRNewswire/ -- Proteolix, Inc. today announced positive clinical data demonstrating that the company's lead product, carfilzomib, has single-agent activity and promotes durable responses in patients with relapsed and refractory multiple myeloma. Carfilzomib is the first in a new class of specific proteasome inhibitors being developed by Proteolix for the treatment of hematologic malignancies and solid tumors. Sundar Jagannath, M.D., Chief of the...

2008-12-08 12:30:00

Lead Oral Candidate Demonstrates Proteasome Inhibition and Anti-Tumor Activity SOUTH SAN FRANCISCO, Calif., Dec. 8 /PRNewswire/ -- Proteolix, Inc., today announced results from a series of in vitro and in vivo studies designed to characterize PR-047, the company's oral proteasome inhibitor. These data were presented today in a poster titled "Preclinical Pharmacology and In Vitro Characterization of PR-047, An Oral Inhibitor of the 20S Proteasome" (Abstract # 3671) at the 50th Annual...

2008-10-23 06:00:11

SOUTH SAN FRANCISCO, Oct. 23 /PRNewswire/ -- Proteolix, Inc., a leader in the discovery and development of novel therapeutics that target protein degradation pathways in cancer and autoimmune diseases, today presented positive data from a Phase 1 clinical trial of carfilzomib (PR-171) in patients with advanced solid tumors at the 20th EORTC-NCI-AACR symposium on "Molecular Targets and Cancer Therapeutics" in Geneva, Switzerland. The Phase 1 clinical trial was designed to assess the safety,...

2008-09-08 09:00:52

SOUTH SAN FRANCISCO, Calif., Sept. 8 /PRNewswire/ -- Proteolix, Inc., a leader in the discovery and development of novel therapeutics that target protein degradation pathways in cancer and autoimmune diseases, today announced the successful completion of a new financing round of $79 million. The Series C round was led by new investor Nomura Phase4 Ventures. New investor Westfield Capital Management and existing investors, Advanced Technology Ventures, Delphi Ventures, Latterell Venture...

2008-08-25 09:00:30

Telik has announced that its small molecule proteasome inhibitor program met a preclinical development milestone by demonstrating anticancer activity in preclinical models of human leukemia. The proteasome is an important cellular structure necessary for the growth and function of cancer cells and inhibition of the proteasome has been shown to promote cell cycle arrest and cancer cell death or apoptosis. Bortezomib, an approved drug for the treatment of multiple myeloma, is based on this...

2008-07-28 15:01:01

Velcade is likely to receive EMEA approval following a positive opinion issued by the EU Committee for Medicinal Products for Human Use for use in previously untreated multiple myeloma patients. Velcade would see considerable uptake if the drug is approved in the first-line setting, due to its proven activity and favorable safety profile compared to current treatment regimens. Velcade (bortezomib; Takeda/Johnson & Johnson) has received a positive opinion from the EU Committee for...


Word of the Day
glogg
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).
Related